NasdaqGS - Delayed Quote • USD
Exelixis, Inc. (EXEL)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 14 | 16 | 14 |
| Avg. Estimate | 0.24 | 0.31 | 1.25 | 1.47 |
| Low Estimate | 0.11 | 0.19 | 1.04 | 1.1 |
| High Estimate | 0.47 | 0.42 | 1.36 | 2.07 |
| Year Ago EPS | 0.12 | 0.25 | 0.65 | 1.25 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 21 | 19 |
| Avg. Estimate | 454.92M | 478.5M | 1.91B | 2.06B |
| Low Estimate | 409.2M | 450M | 1.83B | 1.91B |
| High Estimate | 521M | 547M | 1.97B | 2.26B |
| Year Ago Sales | 408.79M | 469.85M | 1.83B | 1.91B |
| Sales Growth (year/est) | 11.30% | 1.80% | 4.10% | 8.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.15 | 0.16 | 0.09 | 0.21 |
| EPS Actual | 0.12 | 0.25 | 0 | 0.27 |
| Difference | -0.03 | 0.09 | -0.09 | 0.06 |
| Surprise % | -20.00% | 56.20% | -100.00% | 28.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.24 | 0.31 | 1.25 | 1.47 |
| 7 Days Ago | 0.24 | 0.31 | 1.23 | 1.46 |
| 30 Days Ago | 0.23 | 0.31 | 1.23 | 1.46 |
| 60 Days Ago | 0.23 | 0.31 | 1.2 | 1.45 |
| 90 Days Ago | 0.24 | 0.29 | 1.06 | 1.34 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 2 | 2 |
| Up Last 30 Days | 3 | 2 | 5 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | EXEL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 100.00% | -- | -- | 0.80% |
| Next Qtr. | 24.00% | -- | -- | 9.60% |
| Current Year | 92.30% | -- | -- | 4.50% |
| Next Year | 17.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 19.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -4.31% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | Barclays: Overweight to Equal-Weight | 4/11/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/10/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 2/7/2024 |
| Maintains | Stifel: Hold to Hold | 2/2/2024 |
| Maintains | Barclays: Overweight to Overweight | 1/30/2024 |
| Initiated | BTIG: Buy | 12/19/2023 |
Related Tickers
INCY Incyte Corporation
52.82
+0.19%
RARE Ultragenyx Pharmaceutical Inc.
43.38
-1.65%
ACAD ACADIA Pharmaceuticals Inc.
17.07
-0.70%
RCUS Arcus Biosciences, Inc.
14.84
0.00%
CYTK Cytokinetics, Incorporated
67.00
-1.37%
AXSM Axsome Therapeutics, Inc.
65.72
-5.72%
MDGL Madrigal Pharmaceuticals, Inc.
222.26
-2.66%
BBIO BridgeBio Pharma, Inc.
24.95
-0.12%
HALO Halozyme Therapeutics, Inc.
37.81
-0.55%
BMRN BioMarin Pharmaceutical Inc.
90.07
-0.44%